About Broncus
Broncus is a publicly listed company based in San Jose (United States) founded in 1997. Minimally invasive technologies for lung disease treatment are developed. Broncus has raised $82.5 million across 5 funding rounds from investors including Intuitive, Qiming Venture Partners and Abingworth. The company has 200 employees. Broncus has completed 1 acquisition, including Uptake Medical. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Lung cancer. Its competitors include Biodesix, OncoCyte and Riverain Tech; 3 of its 3 listed competitors have raised funding.
Company details
Broncus was founded in 1997 and is headquartered in San Jose, United States. Operations focus on the medical device sector, with minimally invasive navigation, diagnostic, and therapeutic solutions provided for lung diseases. An intellectual property portfolio comprising 75 patents, including issued, licensed, and pending ones, is maintained. The LungPoint Virtual Bronchoscopic Navigation System is utilized for image-guided planning and navigation to lung tumors in a commercial-stage context.
- Headquarters San Jose, United States
- Employees 200
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website broncus.com
- Social LinkedIn X
- Legal Name Broncus Holding Corp.
- Annual Revenue$174.71 K (USD)-97.86as on Dec 31, 2025
- Net Profit-$17.9 M (USD)-16.7as on Dec 31, 2025
- EBITDA-$22.34 M (USD)-15.61as on Dec 31, 2025
- Total Equity Funding$82.5M (USD)
in 5 rounds
- InvestorsIntuitive
& 23 more
- Employee Count200
- Investments & Acquisitions
Funding Insights of Broncus
Broncus has successfully raised a total of $82.5M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $82.5M
- Total Rounds 5
- First Round $29.5M
(Aug 2006)
- Investors Count 24
All 5 funding rounds of Broncus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | Series D | – | FountainVest Partners | ||
| Oct 2020 | Series C | – | Lake Bleu Capital | ||
| Jun 2018 | $15M | Series A | – | – | |
| Dec 2008 | $38M | Series G | – | – | |
| Aug 2006 | $29.5M | Series A | – | Abingworth, Biomedical Sciences Investment Fund |
24 investors in total: 24 institutional.
Investors in Broncus
Broncus has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Intuitive, Qiming Venture Partners and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
FountainVest is involved in investment or financial services. | fountainvest.com | |||
Exome Asset Management is focused on healthcare industry investments. | 2018 | exomeasset.com | New York, United States | |
Summer Capital is engaged in multi-strategy investment advisory services. | summer-cap.com | |||
| lakebleu-cap.com | ||||
Private equity investments are managed across multiple sectors by DCP. | dcpcapital.com | Beijing, China | ||
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Late-stage life sciences investments are managed via VC and PE. | hbmpartners.com | Zug, Switzerland | ||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland |
Investor details for Broncus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Broncus
Broncus is a publicly listed company on the HKEX with ticker symbol 2216 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Sep 2021
- Listed onHKG: 2216
- Listed entityBroncus Holding Corp.
- Exchange sectorHealth technology
- ISINKYG1609T1022
- Share price0.61 HKD · 2026-10-14
- Market capitalisation325,173,297.00 HKD
- Volume (last session)237,500
Financials of Broncus
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.4M HKD | -139.3M HKD | -173.9M HKD |
| 2024 | 63.5M HKD | -119.4M HKD | -150.4M HKD |
| 2023 | 80.3M HKD | -219.9M HKD | -237.7M HKD |
| 2022 | 73.7M HKD | -219.5M HKD | -233.8M HKD |
| 2021 | 84.7M HKD | -1.83B HKD | -250.3M HKD |
Detailed financial statements for Broncus
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Broncus
Broncus has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Uptake Medical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Targeted vapor therapy is developed for endoscopic lung volume reduction. | uptakemedical.com | Tustin, United States | 2005 | Sep 2017 | •••• |
Complete acquisition details for Broncus
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Broncus
5 dated milestones of Broncus across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Broncus is founded.
- Funding First funding round of $29.5M.
- Acquisition Acquires Uptake Medical.
- Funding Latest funding round, Series D,.
- IPO Lists on the stock exchange (IPO).
Competitors of Broncus
Broncus has 3 listed competitors in our database, 3 of them funded. They include Biodesix, OncoCyte and Riverain Tech.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biodesix.com | 2005 | Boulder, United States | $200.16M | 217 | Cancer detection diagnostics assays are developed and offered. | |
| oncocyte.com | 2009 | Irvine, United States | $15.35M | 76 | Non-invasive diagnostic test solutions for cancer treatment are developed. | |
| riveraintech.com | 2008 | Miamisburg, United States | $15M | 25 | Software tools are developed for early lung disease detection. |
Detailed competitors of Broncus
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Broncus
The website of Broncus (broncus.com) receives about 2.2K visits a month.
- Monthly visits2.2K
Top companies in Oncology
3 companies that operate in the same segment as Broncus (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Broncus
Complete news archive for Broncus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Broncus
Broncus was founded in 1997 and raised its 1st funding round 9 years after it was founded.
Broncus is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Broncus is a funded company, having raised a total of $82.5M across 5 funding rounds to date. The company's 1st funding round was a Series A of $29.5M, raised on Aug 2006.
Broncus has 200 employees.
Annual revenue of Broncus is $174.71K as on Dec 31, 2025.
Broncus was founded in 1997 and is headquartered in San Jose, United States. Operations focus on the medical device sector, with minimally invasive navigation, diagnostic, and therapeutic solutions provided for lung diseases. An intellectual property portfolio comprising 75 patents, including issued, licensed, and pending ones, is maintained. The LungPoint Virtual Bronchoscopic Navigation System is utilized for image-guided planning and navigation to lung tumors in a commercial-stage context.
Broncus's top competitors include Biodesix, OncoCyte and Riverain Tech.
Yes, Broncus is publicly traded on HKEX under the ticker symbol 2216.
Broncus has made 1 acquisition, including Uptake Medical.
Broncus has 24 investors. Key investors include Intuitive, Qiming Venture Partners, Abingworth, HBM Healthcare Investments, and Japan Asia Investment.